



Gnubiotics accelerates testing of multivalent-glycan based pipeline candidates against viral entry of COVID-19

In collaboration with the Institute Antiviral Research at Utah State, Gnubiotics has accelerated pre-clinical trials to explore the effects of its multivalent glycan formulations on live SARS-CoV-2 viruses in cell culture as well as evaluating the inhibition of viral-induced cytopathic effects (CPE).

Targeting of glycans known to be present on the SARS-CoV-2 cell surface, which have been shown to be critical to viral binding, is a novel approach under consideration for inhibition of SARS-CoV-2 viral entry and adsorption into target host cells.

Early data has shown sialylated glycans may have an effect on a range of virus including the influenza virus. Gnubiotics remains optimistic that we can be part of the global solution and response to stop the COVID-19 pandemic.

About Gnubiotics: Gnubiotics is a Swiss biotech company specialized in producing glycans to modulate the microbiome of humans and animals, naturally.

Since 2016, Gnubiotics has invested in understanding the science of glycans, specifically their natural properties of selective microbiome modulation. This understanding of glycan structure combined with efficacy data generated on microbial function has prompted our response to join the global fight against COVID-19.

Learn more at www.gnubiotics.com. Follow us at www.linkedin.com/company/gnubiotics.